J. Paul Taylor named scientific director, executive vice president of St. Jude

NLRC5 is an innate immune sensor that plays a crucial role in PANoptotic cell death

NLRC5 plays a previously unknown role as an innate immune sensor, triggering cell death, according to new research from St. Jude Children’s Research Hospital. The findings, published in Cell, show how NLRC5 drives PANoptosis, a prominent type of inflammatory cell death.

June 21, 2024

Vol.50 No.25

Clinical Roundup

T-cell aging not limited by organismal age, allowing healthy cells to proliferate in perpetuity

While most cell types experience a functional decline after years of proliferation and replication, T cells can proliferate seemingly indefinitely and without detriment.

June 14, 2024

Vol.50 No.24

In Brief

Andrew Smith named chair of St. Jude Diagnostic Imaging Department

Andrew Smith was named chair of St. Jude’s Diagnostic Imaging Department. He succeeds Beth McCarville, who was interim chair of the department since the death of Zoltan Patay, who held the position from 2017 to 2022.

April 19, 2024

Vol.50 No.16

In Brief

St. Jude adds $13M project to Research Collaboratives program

St. Jude Children’s Research Hospital invested nearly $13 million toward a research collaboration with scientists at Columbia University, Duke University, and Stanford University to expand the understanding of G-protein coupled receptors, which are vital proteins that impact human health and disease.

January 19, 2024

Vol.50 No.03

In Brief

WHO, St. Jude coordinate evacuations for children with cancer from Gaza to Egypt, Jordan

About 12 children with cancer or other blood disorders have been evacuated, with their companions, from the Gaza Strip in the occupied Palestinian territory to Egypt and Jordan so they may continue their treatment safely. Additional children are expected to be evacuated for cancer treatment as part of this initiative.

November 10, 2023

Vol.49 No.42

In Brief

St. Jude, University of Cincinnati receive $4M from NCI to study immunotherapy in diffuse midline glioma

A multi-investigator team has received $4 million from NCI to study immunotherapy in diffuse midline glioma.

October 27, 2023

Vol.49 No.40

J. Paul Taylor named scientific director, executive vice president of St. Jude

YOU MAY BE INTERESTED IN

NLRC5 is an innate immune sensor that plays a crucial role in PANoptotic cell death

T-cell aging not limited by organismal age, allowing healthy cells to proliferate in perpetuity

Andrew Smith named chair of St. Jude Diagnostic Imaging Department

St. Jude adds $13M project to Research Collaboratives program

WHO, St. Jude coordinate evacuations for children with cancer from Gaza to Egypt, Jordan

St. Jude, University of Cincinnati receive $4M from NCI to study immunotherapy in diffuse midline glioma

Renew today!

Subscriber content

Login